S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
NYSE:TEVA

Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

$10.26
-0.12 (-1.16%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.16
$10.40
50-Day Range
$8.32
$11.37
52-Week Range
$6.78
$11.44
Volume
6.35 million shs
Average Volume
10.75 million shs
Market Capitalization
$11.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.0% Upside
$10.67 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.77mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.42%
From $2.40 to $2.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

936th out of 1,049 stocks

Pharmaceutical Preparations Industry

455th out of 514 stocks


TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Hot craft spirits opportunity you don't want to miss
Award winning products. Global distribution. New distillery. New products.pixel
Hot craft spirits opportunity you don't want to miss
Award winning products. Global distribution. New distillery. New products.pixel
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Confirmed)
2/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-14.14%

Debt

Sales & Book Value

Annual Sales
$15.14 billion
Cash Flow
$3.64 per share
Book Value
$10.19 per share

Miscellaneous

Outstanding Shares
1,110,565,000
Free Float
1,101,458,000
Market Cap
$11.39 billion
Optionable
Optionable
Beta
1.20

Key Executives

  • Mr. Eliyahu Sharon Kalif (Age 50)
    Exec. VP & CFO
    Comp: $1.74M
  • Mr. Eric DrapeMr. Eric Drape (Age 61)
    Exec. VP of Global Operations
    Comp: $1.91M
  • Mr. Mark SabagMr. Mark Sabag (Age 52)
    Exec. VP of International Markets Commercial
    Comp: $1.79M
  • Dr. Sven Dethlefs Ph.D. (Age 54)
    Exec. VP of North America Commercial
    Comp: $1.72M
  • Mr. Amir Weiss (Age 46)
    Sr. VP & Chief Accounting Officer
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations
  • Mr. David M. Stark (Age 54)
    Exec. VP & Chief Legal Officer
  • Kathleen Veit
    Sr. VP, Global Compliance & Ethics Officer
  • Mr. Eli ShaniMr. Eli Shani
    Exec. VP of Global Marketing & Portfolio
  • Ms. Galia Inbar (Age 48)
    Exec. VP, Chief HR Officer & Corp. Affairs













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2023?

9 analysts have issued 1-year target prices for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2023?

Teva Pharmaceutical Industries' stock was trading at $9.12 on January 1st, 2023. Since then, TEVA stock has increased by 13.5% and is now trading at $10.35.
View the best growth stocks for 2023 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in January. As of January 15th, there was short interest totaling 25,020,000 shares, a decrease of 20.5% from the December 31st total of 31,470,000 shares. Based on an average daily trading volume, of 9,750,000 shares, the short-interest ratio is presently 2.6 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Thursday, November, 3rd. The company reported $0.56 EPS for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The business earned $3.60 billion during the quarter, compared to analyst estimates of $3.86 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 26.97% and a negative net margin of 8.52%.

Is Teva Pharmaceutical Industries a good dividend stock?

Teva Pharmaceutical Industries (NYSE:TEVA) pays an annual dividend of $1.01 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for TEVA.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $2.40-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (1.94%), Harel Insurance Investments & Financial Services Ltd. (1.36%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Strs Ohio (0.11%), Assenagon Asset Management S.A. (0.09%) and ARK Investment Management LLC (0.02%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $10.35.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.49 billion and generates $15.14 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 1/31/2023 by MarketBeat.com Staff